Neoadjuvant sintilimab and chemotherapy followed by transoral surgery for HPV-positive resectable oropharyngeal cancer: a single-arm, two-centre, phase 2 trial.

Additionally, 75% of patients (9/12) with undetectable ctHPV-DNA after the neoadjuvant immunochemotherapy achieved pCR, compared with only 20% (1/5) among those with persistent ctHPV-DNA detection, though the difference did not reach statistical significance (p = 0.10; Fig. 4 E).

also in 111,027 other papers